Skin care company Crown Aesthetics reported on Wednesday the receipt of Medical Device Single Audit Programme (MDSAP) certification upon a rigorous audit by BSI (British Standards Institute).
Following MDSAP certification, the company will continue selling SkinPen, the first FDA cleared microneedling device, in Canada, Australia, Brazil and Japan.
MDSAP allows a single regulatory audit of a medical device manufacturer's quality management system to satisfy the requirements of multiple regulatory authorities. It covers the requirements of ISO 13485:2016 plus Good Manufacturing Practices (GMP) for each applicable regulatory authority. MDSAP is validation of the company's world-class service and pursuit of quality, safety and efficiency.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Saluda Medical secures CE certification for EVA Sensing Technology in Europe